Overall, our findings strongly support further investigation for the clinical translation of B7-H3- and CSPG4-targeted CAR T cell-based immunotherapies for the treatment of anaplastic thyroid cancer. This evidence concerns the gene CSPG4 and thyroid gland undifferentiated (anaplastic) carcinoma.